Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
Khaled Musallam, Group Chief Research Officer Burjeel Holdings, Adj. Prof. Khalifa University and Weill Cornell Medicine (NY), shared on LinkedIn:
”Pleased to share results from our de-LIGHT study out now in the British Journal of Haematology. What makes this data special and what’s its added value:
- Most studies evaluating the impact of anemia and iron overload on morbidity and mortality outcomes in beta-thalassemia (including those from our group) used spot indices or followed patients over short or defined periods of time. In de-LIGHT, it took tremendous effort but we were able to capture a lifetime observation since diagnosis looking at anemia/iron vs outcomes over a median follow up of 38 years in 500+ patients
- We defined patients as having NTDT or TDT based on lifetime exposure to transfusions (rather than their status ‘now’ or in the past 6 months)
- We used a lifetime anemia and iron control index (LAICI) defined based on adherence to TIF guidelines recommendations in NTDT and TDT. This was significantly and independently associated with overall survival and incidence of various morbidities.
Thalassemia treatment is lifelong, and evidence-based, optimal management of anemia and iron overload should persist over the entire disease course and cannot be sporadic.”
Read the full article here.
Article: Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study
Authors: Khaled Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone, Antonino Giangreco, Maria Concetta Renda, Emanuela Fecarotta, Antonio Troia, Antonino Giambona, Giovan Battista Ruffo, Efthymia Vlachaki, Theodora M. Venou, Paolo Ricchi, Brunella Ziello, Marilena Serra, Elena Colizzi, Filomena Longo, Martina Culcasi, Aurelio Maggio

Stay updated on the latest scientific advances in the field of hematology with Hemostasis Today.
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS
-
Jan 29, 2026, 04:42Jecko Thachil on ‘Break Through’ Thrombosis Despite DOAC Use
-
Jan 28, 2026, 13:55Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
-
Jan 28, 2026, 13:35Louise St Germain Bannon Invites You to Submit Your Work to JTH and RPTH
-
Jan 28, 2026, 13:26Livia Stanger and Colleagues Link CS014 to in Vivo Thrombosis
-
Jan 28, 2026, 13:14Robert Campbell Congratulates Izabella Andrianova for Her Recent Publication in JTH
